Panalgo and Navidence team up to standardize phenotype definitions for real-world data analytics

Panalgo and Navidence have formed a strategic partnership to embed clinically reviewed phenotype definitions into analytics workflows, aiming to support more consistent and efficient real-world data (RWD) analyses.

As the use of RWD continues to expand, the need for consistent and transparent approaches to defining patient populations has become increasingly important. In response, Panalgo, a Norstella company, has partnered with Navidence to integrate clinically reviewed phenotype definitions directly into Panalgo’s Instant Health Data (IHD) platform, enabling standardized patient cohort definitions to be applied within existing analytic workflows.

Across the RWD landscape, identifying and validating disease and therapy definitions remains a resource-intensive process. Analysts often rely on manual methods to assemble coding systems such as ICD, SNOMED, and NDC. According to the companies, this process can take between 8 and 12 weeks per project and may introduce variability between studies, potentially affecting the consistency and reliability of results.

The integration is intended to address these challenges by making Navidence’s library of clinically reviewed phenotype definitions available directly within the IHD platform. Users can search, select, and apply predefined definitions by therapeutic area or clinical indication without leaving the analytics environment. This approach supports a more streamlined transition from study design to cohort creation and analysis, reducing reliance on manual code development. These predefined definitions include diseases, therapies, and associated code sets.

In addition to improving efficiency, the integrated workflow provides greater visibility into the materials supporting each definition. Users can review underlying code sets, metadata, and source documentation directly within the platform, supporting transparency and supporting reproducible and auditable analyses. Navidence code lists function in the same way as existing IHD code lists, allowing users to create patient cohorts, dashboards, and analyses using familiar tools. The definitions can also be used alongside Panalgo’s Ella AI capabilities, which are designed to support cohort development and accelerate analytic workflows.

Aaron Kamauu, CEO and co-founder of Navidence, highlighted the role of standardized definitions in improving evidence quality, stating:

“Real-world evidence is only as good as the underlying definitions allow. This partnership brings clinical rigor directly into the analytics environment. By embedding our definitions into IHD, we enable researchers to define once and trust everywhere: reducing variability, increasing transparency, and improving the quality of real-world evidence.”

Kevin D’Ambrosia, Chief Revenue Officer, HEOR, RWD and RWE at Norstella, focused on the operational implications of the integration, noting:

“This partnership is about removing friction from one of the most time-consuming and risk-prone parts of RWD analytics. By integrating clinically validated definitions directly into IHD, we’re helping teams move faster from question to insight while improving consistency, transparency, and trust in the results.”